Cytokinetics, Incorporated (CYTK) Earnings Call Transcript & Summary

November 5, 2025

NASDAQ US Health Care Biotechnology earnings 61 min

Earnings Call Speaker Segments

Diane Weiser

executive
#1

Good afternoon, and thank you for being with us on today's call. Robert Blum, our President and Chief Executive Officer, will kick things off with a look at the quarter and what's happened recently. Andrew Callos, EVP and Chief Commercial Officer, will discuss commercial readiness efforts for aficamten. Fady Malik, EVP of R&D, will share updates on the clinical development program and medical affairs work for aficamten. Stuart Kupfer, SVP and Chief Medical Officer, will give updates on the clinical development program for omecamtiv mecarbil and ulacamten. Sung Lee, EVP and Chief Financial Officer, will walk through a financial overview of the quarter just ended. And last, Robert will offer closing remarks and go over the key milestones we expect for the rest of 2025. Please be aware that parts of what we discuss next, including our answers to questions, include statements about future events and performance rather than historical facts, and these are forward-looking statements. What actually happens could differ materially from what these forward-looking statements project. Details about factors that could make our actual results differ materially from those in these forward-looking statements can be found in our SEC filings, including our current report on our third quarter 2025 financial results furnished to the SEC today on Form 8-K. We have no obligation to update any forward-looking statements after this call. I'll now hand the call over to Robert.

Robert Blum

executive
#2

Thanks, Diane, and I appreciate everyone being on the call today. This last quarter proved extremely productive and pivotal for Cytokinetics. We've moved substantially forward on the company's key priorities as we head toward the close of the year, when we're hoping to secure what would be our first possible FDA approval of aficamten for oHCM patients. Everything we accomplished over the quarter was aimed at getting ready for that milestone, which included keeping up productive conversations with the FDA, wrapping up critical launch preparedness work on the commercial side, and strengthening our capital position. During the quarter, we had our late-cycle meeting with the FDA. As we'd said before, at that meeting we talked through the REMS program we proposed, covering elements to assure safe use, or ETASU, along with the post-marketing requirements we anticipate. Before that meeting, the FDA had given us its feedback on our proposed REMS and the label for aficamten. And given how we've been exchanging information and talking with the FDA so far, we still anticipate a differentiated label and risk mitigation profile for aficamten should the FDA grant approval. Every GCP inspection the FDA required has now been finished, with no observations flagged. On top of that, as of today, the FDA hasn't told us it plans to run any pre-approval inspections. We're eager to keep the dialogue going with the FDA as we approach the PDUFA date. Over recent months, we've also pushed harder on commercial readiness, bringing our commercial field sales colleagues on board and completing our promotional campaigns and patient support programs, all with the goal of further setting ourselves apart in how we present ourselves commercially. Meanwhile, in Q3, we hit a major clinical milestone within the aficamten development program. We shared the positive primary results from MAPLE-HCM, showing aficamten's superiority over metoprolol among oHCM patients, which calls into question the status quo that has long governed treatment for this disease. We intend to submit a supplemental NDA for MAPLE-HCM after aficamten potentially gains its initial FDA approval. Until then, though, we think these findings could help spur some prescribers into action and help open up more of the market once aficamten is initially introduced, which may translate into a faster commercial launch. Right on the heels of aficamten's possible approval and launch in the United States comes the anticipated potential approval of aficamten in the EU. During the quarter, the EMA sent us the Day 120 List of Questions, and we filed our answers afterward. More recently, we've kept engaging with the EMA and are getting Day 180 responses ready. The ongoing interactions have us encouraged, and we anticipate a final decision from the European Commission in the first half of next year, potentially even toward the earlier part of the year, considering how quickly our review has moved so far. At the same time, our launch preparations in Europe are progressing well, centered on market access planning, medical education, and connecting with the cardiology community, so we build a solid foundation for a successful introduction of aficamten across Europe. Additionally, we keep collaborating intensively alongside Sanofi to back the possible clearance of aficamten within China, which would expand the worldwide chance further and strengthen our dedication to ensuring this treatment reaches patients across the globe. To accomplish everything here, we are lucky to hold a robust balance sheet, which we strengthened even more this quarter via our convertible note offering. As Sung will detail, that deal not only supplies extra capital at this crucial moment but also delivers financial flexibility. Finally, we keep generating momentum throughout our wider pipeline at this key turning point in our corporate evolution, showing our continued pledge to lasting innovation and growth over the longer term. With that said, I'll now hand the call over to Andrew, please.

Andrew Callos

executive
#3

Thanks, Robert. We're still seeing solid momentum on the commercial readiness front as we head toward a possible FDA green light for aficamten next month. Like Robert said, the conversations we've had with the FDA so far have strengthened what we expect: a differentiated risk mitigation profile rooted in REMS and the label, and we've locked in both our go-to-market plans and our promotional campaign. If approval comes through in December as anticipated, we'll kick off the launch right away. Within a matter of days, our website, patient navigators, and patient support services will all be up and running, so we can start helping physicians and patients along their treatment journey. Soon after that, at the start of January, our cardiovascular sales and medical teams — having completed all their training — will be in the field engaging with healthcare professionals as we shift into full commercial launch, followed by product availability and REMS operations. To ensure this launch is smooth and makes a strong impression, we have made a significant investment in developing the right team and the right infrastructure. During the last several months, we have built a robust, deeply experienced cardiovascular sales team, and our field sales representatives come with an average of over 20 years in the industry along with 14 years in cardiovascular. The people on our sales force have deep experience and understand what it takes to bring a new medicine to market in a specialty area. They're committed and wrapping up their training, so the entire group should be prepared to start engaging HCPs just days after the FDA gives its approval. Since early September, part of that team has already been working in the field, making introductions for Cytokinetics to important oHCM HCPs and delivering education about the disease. This is central to how we plan to launch, and it reflects both our values and our goal of offering a distinct, patient-focused treatment experience — one designed from scratch around aficamten. We want the approach to stay straightforward and cohesive at every point where HCPs and patients interact. This model relies on a very capable group of patient navigators, who serve as the main point of contact across the entire patient journey. Those navigators are already in place and have either completed or are wrapping up their training, together with their preparations for the expected approval, so that everything is ready. We have built a unique and persuasive promotional campaign aimed at HCPs that highlights what sets aficamten apart along with the core features of our REMS program. Our expectation is that this campaign will communicate aficamten's clinical value in a clear way and help generate wide awareness among cardiologists. Before we launch, we're still talking with payers, helping them understand what our clinical trial showed and how much HCM costs both clinically and economically. We continue to feel good about reaching parity access by the latter part of 2026. The key thing is that our approach centers on comparable access, while we aim to stand apart through aficamten's clinical profile, our REMS program, and the full set of tailored support offerings we provide to patients. With a potential approval now just weeks away, I'm happy with where we are on commercial prep and launch readiness, and I'm confident we can move fast and well should aficamten get approved. When we think about how we'll track the speed and momentum of our launch once approval comes, a handful of important measures will be our focus. The first is how broadly HCPs are prescribing, which we gauge by counting the HCPs actively writing scripts. The second is how deeply they're prescribing, which we gauge through prescription volume and the number of HCP writes for aficamten. To drive fast uptake, we'll move quickly to bring existing CMI prescribers on board, aiming to widen the prescriber base to those treating HCM who haven't yet written a CMI prescription. Let me be more specific about what we were trying to accomplish. During the first few weeks of January, we wanted our cardiology account specialists in the field to reach nearly every one of the approximately 650 HCPs — those account for around 80% of HCM prescribing up to now. The third thing we track is the number of patients taking aficamten. We'll be watching patient uptake closely and providing support, which includes when patients switch over to the commercial drug, along with adherence, compliance, and persistency. Through these metrics, we'll get an early read on the pace of our launch, where it's heading, and how well we're executing commercially overall — and that execution is all about growing the category and building preferential share in a market that keeps expanding. Finally, we're not just looking at the U.S. Turning to Europe, our planning for a potential commercial release of aficamten there has moved forward considerably. We recently appointed a General Manager for Italy, and that person joins existing team members in the U.K., France and Germany. In addition, we have begun the process of recruiting and hiring the full German commercial organization, which includes field sales representatives. On top of that, we are preparing dossiers for upcoming discussions with HA bodies across major EU nations. Assuming potential EMA approval arrives in the first half of 2026, launching in Germany during the first half of 2026 is still on schedule, and additional countries will follow in '26 and '27. I'll now pass the call over to Fady.

Fady Malik

executive
#4

Thanks, Andrew. Over the quarter, we were glad to share fresh data that strengthens the case for aficamten's distinct profile and what it could mean for HCM patients. In particular, we delivered positive primary results from MAPLE-HCM at the ESC Congress, and those were published at the same time in the New England Journal of Medicine. Those findings, demonstrating that aficamten is superior to metoprolol, mark a watershed moment in treating oHCM. Patients given aficamten saw a meaningful gain in exercise capacity, whereas those receiving metoprolol declined, which calls into question the decades-old rationale for beta blockers as the standard of care in this disease. That result has echoed loudly throughout cardiology, as we heard directly from numerous healthcare professionals and key opinion leaders who were on site at ESC. Beyond the exercise capacity benefit, aficamten generated greater improvements in symptoms, gradients and cardiac biomarkers than metoprolol did. Those improvements held consistently across every prespecified subgroup, reinforcing confidence in how robust the findings are. Importantly, adverse events looked alike between the 2 groups, and aficamten's safety in MAPLE-HCM matched what earlier studies showed. Along those lines, as the evidence behind aficamten grows, so does our confidence in its steady safety profile. In an updated integrated safety analysis covering nearly 700 patient years of exposure drawn from REDWOOD-HCM, SEQUOIA-HCM, FOREST-HCM and now MAPLE-HCM as well, aficamten proved well tolerated, with a low incidence of LVEF below 50% across extended exposure periods, and no occurrences tied to a serious event of heart failure. Long-term aficamten treatment has likewise been shown not to carry an elevated risk for atrial fibrillation. Looking forward, later this month at the AHA scientific session, we're pleased to have 3 late-breaker presentations with additional MAPLE-HCM data offering new insights into these results; regarding the ongoing clinical trial program for aficamten, our next major data milestone will be the readout of ACACIA-HCM, the pivotal Phase 3 trial in nHCM; we finished enrolling the primary cohort, excluding Japan, in the first quarter of 2025, and we now expect to report top line results from this cohort of ACACIA-HCM in the second quarter of 2026. In the third quarter, we finished enrolling patients in the Japan cohort, which closed ACACIA-HCM enrollment worldwide. Should ACACIA-HCM read out positively, it offers a chance to address the needs of a highly underserved patient population and a significant opportunity to broaden aficamten's therapeutic impact. Our confidence in aficamten's therapeutic potential in nHCM rests on the existing body of evidence from the nHCM cohort of REDWOOD-HCM and is bolstered by their longer term follow-up in the FOREST-HCM trial as recently reported. At the Heart Failure Society of America meeting in late September, we presented new data covering at least 96 weeks of treatment in these nHCM patients. In an open-label study, you observed that among patients receiving aficamten, 79% experienced improvement of at least one NYHA functional class. There was also a mean gain of 11.2 points on the KCCQ Clinical Summary Score, plus favorable changes in cardiac biomarkers. Only a small number of patients had LVEF below 50, and every one of those cases resolved following dose reduction or a brief pause in treatment. Since the patient groups and dosing approach in ACACIA-HCM are similar, we hold hope that these findings will be reproduced there. In parallel with our clinical work, our Medical Affairs team has been highly engaged, connecting broadly with the HCM community as we get ready for launches across the U.S. and Europe. They recently ran advisory boards in both the U.S. and Europe, and they connected with the HCM physician community at ESC and HFSA, along with institutional visits within their regions. Our therapeutic medical scientists are now established in Germany, and we have medical directors based in Germany, the U.K. and France, with support from our regional group in Switzerland. In the U.S., our field team has begun working alongside newly recruited sales counterparts to hold compliant introductory meetings with key opinion leaders and healthcare professionals; at this point I'll hand things to Stuart for updates on our heart failure trials that are underway.

Stuart Kupfer

executive
#5

Appreciate it, Fady. Over the course of the quarter, we kept running COMET-HF, the confirmatory Phase 3 study of omecamtiv mecarbil in symptomatic heart failure patients whose ejection fraction is severely reduced, below 30%. Even while on maximally tolerated guideline-directed therapies, these individuals continue to face elevated danger of repeated hospitalization and death. The purpose of COMET-HF is to verify what the positive Phase 3 GALACTIC-HF trial showed, but in a sicker HFrEF group, where we think this mechanism could produce even stronger cardiovascular risk reduction. Back in October, we held an investigator meeting in Europe, and it showed enormous excitement about COMET-HF. A large number of those investigators had taken part in GALACTIC-HF, so it was genuinely great to witness their ongoing excitement regarding what omecamtiv mecarbil might offer. At this point, more than 75% of sites across North America and Europe are activated, and we keep activating sites globally. Our expectation is that patient enrollment in COMET-HF will carry on into 2026. We are also still running AMBER-HFpEF, the Phase 2 trial of ulacamten in symptomatic heart failure patients with preserved ejection fraction of at least 60%. Through inhibition of cardiac myosin to lessen hypercontractility, ulacamten holds a distinctive position to tackle the diastolic dysfunction underlying this HFpEF subgroup. Roughly half of all heart failure cases are HFpEF, and it stays a space of substantial unmet need with few treatment choices. Enrollment in AMBER-HFpEF is moving forward, and we anticipate finishing cohorts 1 and 2 in 2026, which will guide FDA interactions and the choices about moving toward possible registrational studies. We are happy with how these ongoing clinical trials continue to be executed, each covering a different form of heart failure, which demonstrates our ongoing dedication to further advancing innovative medicines in our specialty cardiology franchise; and with that, I will hand things over to Sung.

Sung Lee

executive
#6

Thanks, Stuart. We're glad to walk you through how Q3 2025 turned out financially. Starting on the balance sheet: when the third quarter ended, our cash and investments totaled about $1.25 billion, compared with $1 billion when the second quarter of 2025 wrapped up. What drove that sequential increase? Net proceeds of $327 million, which came from our issuance of convertible senior notes due 2031 with an aggregate principal amount of $750 million, plus the simultaneous exchange of $399.5 million in aggregate principal amount of our 2027 notes. Together, those moves accomplish what we set out to do — position the company with financial flexibility before aficamten potentially launches for oHCM. Excluding the net proceeds from this deal, our cash position would have fallen by about $112 million from one quarter to the next. In October, Royalty Pharma's Tranche 5 loan gave us $100 million in proceeds, and that should let us finish 2025 with roughly $1.2 billion in cash and investments. Second-quarter R&D expenses reached $99.2 million, up from $84.6 million a year earlier in 2024. The main reasons for that rise were the progress of our clinical trials and greater costs tied to personnel, stock-based compensation among them. For the third quarter of 2025, G&A expenses were $69.5 million, whereas the same period in 2024 saw $56.7 million. Higher spending on getting ready for commercial launch, along with greater costs tied to employees—stock-based compensation included—was the primary driver behind this rise. For the third quarter of 2025, we recorded a net loss of $306.2 million, equal to $2.55 per share, compared with a net loss of $160.5 million, or $1.36 per share, during the same quarter in 2024. Included in that third-quarter 2025 net loss is a debt conversion expense of $121.2 million, which came about from the induced exchange of $399.5 million in aggregate principal amount of the 2027 notes. Turning now to our financial guidance: for the full year 2025, we are tightening our GAAP operating expense range to $680 million to $700 million, a reduction from the earlier range of $670 million to $710 million. We anticipate that GAAP operating expense will include somewhere between $110 million and $120 million in stock-based compensation. If you strip out stock-based compensation from GAAP operating expense, the range that remains is $560 million to $590 million. With 2025 drawing to a close, we've made meaningful moves to strengthen our balance sheet and give it more flexibility. That leaves us in a solid position ahead of the U.S. PDUFA date for aficamten, a possible EU approval during the first half of 2026, and results from ACACIA-HCM that we expect to read out in the second quarter of 2026; with that, I'll turn things back over to Robert.

Robert Blum

executive
#7

Thanks, Sung. During this quarter, we achieved meaningful progress throughout the organization. We shared further data that keeps confirming our groundbreaking and leading science, and strengthens the distinctive profile of aficamten, while we also completed our preparations for commercial launch readiness and sustained momentum throughout our pipeline. These achievements highlight the focus, rigor and commitment of our teams as we get closer to the single most significant milestone in our company's history. To assist us in getting ready for this crucial stage in the company's evolution, we were happy to welcome James Daly onto our Board of Directors during this quarter. Jim offers over 30 years of worldwide biopharma commercial leadership experience, including long-standing senior commercialization expertise gained while serving as Chief Commercial Officer at Incyte and in senior commercial positions at Amgen, along with current Board positions at top commercial biopharma companies; we anticipate his guidance and oversight now as a Board member at Cytokinetics. As we near what could be our first FDA approval at Cytokinetics, I want to express gratitude to our employees, our partners and our shareholders for their ongoing trust and support. We're approaching a key turning point for our business. After years of careful spending on our science, pipeline, infrastructure, and capital structure, we've reached an important milestone, and that sets the stage for our intended shift into a completely integrated commercial organization. Right now, we aren't just watching from the sidelines — we're actively helping to write the next part of our company's story. In the near term, we remain focused on possible regulatory clearances as well as commercial launch and momentum. I have great confidence in how strong our teams are and how clear our shared vision is, which is now turning into execution. With that said, I'll walk through the milestones ahead. Regarding aficamten, our plan is to keep moving forward on NDA review work alongside the FDA, aiming to back a possible U.S. green light for the drug before this year wraps up. We're looking to push ahead with go-to-market approaches and keep getting ready to launch aficamten across the United States. In Germany, we anticipate carrying on with go-to-market planning, while broadening commercial readiness efforts throughout Europe during 2025, all as preparation for a potential EMA approval of aficamten in the first half of 2026. We plan to keep working alongside Sanofi to help secure a possible approval for aficamten in China, assuming the NMPA gives the green light. Also, we anticipate sharing topline data from the primary cohort of ACACIA-HCM during Q2 of 2026, while carrying on with enrollment and running the adolescent cohort of CEDAR-HCM as we move through 2026. When it comes to omecamtiv mecarbil, our plan is to maintain enrollment and continue conducting COMET-HF across 2026. As for ulacamten, we intend to keep enrolling patients and running AMBER-HFpEF throughout 2026. Last but not least, regarding work done before human trials and continuing studies, our plan is to keep advancing those efforts along with research efforts aimed at further programs centered on muscle biology; and at this point, moderator, please go ahead and let us begin taking questions from participants.

Gena Wang

analyst
#8

There's a lot I'd like to ask about the approval, but I'll leave those for others on the call. So I'll pose one thing about the ACACIA data. I believe you said those results are expected during 2Q '26. As I recall, you introduced pVO2 as a dual primary endpoint in response to regulatory feedback from Europe and Japan. In theory, then, the drug ought to be approved if either one of the two primary endpoints is achieved. So — but if pVO2 is missed, do you expect any trouble getting approval in Europe and Japan? My assumption is that the U.S. will be entirely fine provided one endpoint is hit.

Robert Blum

executive
#9

I'll have Fady address that.

Fady Malik

executive
#10

Gena, in my view, figuring out what ensures an approval is genuinely tough. Clearly, it hinges on how large the other findings turn out to be. It hinges on the safety profile, it hinges on many factors. Still, my sense is that the study would be viewed as favorable under our statistical analysis plan if either endpoint comes out positive, though you would want to see them at minimum shifting in a shared direction. You would want to see effect sizes that strike us as clinically meaningful. You would want to see consistency across the remaining endpoints. So I believe every one of those elements feeds into how regulators judge whether a trial not only achieved statistical significance, but also stands for a clinically meaningful therapeutic in the field.

Salim Syed

analyst
#11

Given how much focus this study is getting, I want to ask something about ACACIA as well. And I apologize for how detailed this p-value question is. But Fady, from what I understand, the p-value in the ACACIA trial is divided evenly between KCCQ and peak VO2, at 0.025 apiece. And if someone were to argue the other side for a moment, I'm just wondering why that approach makes more sense right now compared with what ODYSSEY did, where the weighting favored KCCQ at 0.04 and the result came in at a p-value of 0.06, which nearly reached significance and was also a stronger p-value than what ODYSSEY showed on the peak VO2 measure. And remember, the trial only requires one measure to hit statistically for it to succeed. On that note, even though the study remains blinded, if you chose to, would it be possible to alter how the 2 endpoints are weighted in ACACIA prior to unblinding the results?

Robert Blum

executive
#12

Once again, I sort of walk through the — as I mentioned before, a positive result isn't automatically a meaningful one. You could — I believe the ODYSSEY trial failed, and the KCCQ difference was 2 or 3, I don't recall the precise figure, but fairly modest, and I doubt it would — when you look at the magnitude of effect, regulators would find that compelling; so we designed this trial with 0.025 for each based on our belief in a solid clinical effect at KCCQ of 5 points and peak VO2 improved by 1.0; now that powering — having 90% power for each of those magnitudes doesn't mean the trial succeeds only when we hit those magnitudes. The smallest, I suppose, positive difference for those endpoints is considerably lower and enters a territory where it's likely arguable whether the effect size matters or not. So we believe each endpoint has been adequately powered. We believe splitting alpha equally gives us a chance to win the best on each endpoint. And right now, I don't expect us to make any modifications to that.

Zaki Molvi

analyst
#13

It's Zaki here, filling in for Akash. So, turning back to Nonobstructive — you mentioned that Bristol's ODYSSEY trial included an outlier placebo. And from our perspective, it looks almost as if their standard deviation on KCCQ specifically ended up larger than their protocol had anticipated. So with ACACIA, you decided to keep the study at a size comparable to ODYSSEY, but with an alpha split that's even more aggressive. So I'd just like to hear, regarding what you can see on blinded variability, what makes you confident that, first, you aren't underpowered relative to ODYSSEY, and second, that placebo is in fact behaving consistently with your assumptions concerning that 5-point placebo-adjusted delta on KCCQ?

Fady Malik

executive
#14

Well, your final point can't really be answered, since we're blinded — we have no idea what the placebo effect looks like in ACACIA. What we do is track the variability across the combined data set, and at this stage, that variability seems to fall inside our assumptions. So my view is that we have adequate power given the global variability. And once more, I'll simply note that the variability we've seen in KCCQ, across a number of trials we've conducted with that metric, tends to sit around a 15-point range, which matched what we saw with SEQUOIA, and it has matched other studies we've run in that space. And as I see it, the indication isn't really any different right now; so I think we're following along with our assumptions, and for the moment, we'll simply let things unfold and find out how they read out next year.

Robert Blum

executive
#15

I'd also like to point out that how much variability you see depends on several things — for instance, how much experience a site has in running trials like this one. And please keep in mind that, in our view, one approach to keeping variability in check, which is what we've done, is to work with sites that have a great deal of experience carrying out clinical research with aficamten, something that has already been borne out historically in the studies we ran before. So we do think that works in our favor.

Carter Gould

analyst
#16

Perhaps ACACIA can take a pause for a moment. Andrew went through many figures that you'll be keeping an eye on. Which of those figures do you expect to provide to the investment community? Is there any one of them you can commit to today? Also, do you expect to block third-party prescription data at launch?

Robert Blum

executive
#17

Andrew?

Andrew Callos

executive
#18

Regarding the 3 metrics I mentioned — prescribing breadth, prescribing depth, and patient volume — those are the ones we intend to share. No, we won't be providing targets or revealing what those figures would be. When it comes to data, the distribution here is quite limited, and the REMS is what drives that. The specialty pharmacies — or 2 of them — won't be reporting data. That reporting will come from us on a quarterly basis. There are also pharmacies that will qualify as IDN pharmacies through large healthcare systems. A lot of those will flow through syndicated data, though that represents only a very small share of our total volume, perhaps roughly 20% to 30%; so if you're looking at syndicated data from IQVIA or Symphony or one of those sources, the complete picture won't be anywhere near what you see, but we definitely will provide that picture on a quarterly basis.

Jim Condulis

analyst
#19

I want to pose one more question regarding ACACIA, and once again it concerns blinded data. I was wondering, when it comes to blinded safety data, what sort of visibility do you actually have, and perhaps what does the LVF less than 50% rate look like? Clearly, I'm not asking for anything specific, but rather how it stacks up against, let's say, what was observed in SEQUOIA and Obstructive. I'm just curious whether there's any color there.

Robert Blum

executive
#20

Yes, I'll attempt to tread carefully here. All I'll say is that nothing in the blinded data has come as a surprise given what we've seen so far.

Cory Kasimov

analyst
#21

Let me return to the launch that's still ahead. I'm wondering whether you expect that standing up one more REMS program at those HCM clinics that already prescribe mavacamten will act as an obstacle, one that we ought to figure will decelerate how quickly the launch unfolds in its first stretch? Or by now is getting centers signed up a fairly uncomplicated matter?

Robert Blum

executive
#22

I'll turn it over to Andrew for his thoughts. Perhaps I should begin by noting that we hold in high regard the reality that workflows already exist and have been modified. As Andrew pointed out earlier, our aim is to support a REMS program and its rollout in a way that delivers a smoother, simpler encounter for physicians, patients and pharmacists inside the workflows they've established. Andrew, maybe you could say more.

Andrew Callos

executive
#23

Yeah, that's a fair question. A large number of centers are being written at by physicians these days. So one aim would be getting a REMS program that's differentiated, working together with MAPLE and SEQUOIA, to push more of these across the finish line, as it were, into prescribing. That means a new workflow for them. For those with a workflow already in place, what happens in the office centers on echo for titration and monitoring. That part is comparable. So you'll potentially have echo monitoring at, let's say, a different frequency, or the option to titrate upward at every monitoring point. So it's the same sort of workflow, in a sense; therefore we don't expect that the workflow for monitoring, or the monitoring window, is going to cause must act, particularly among high users and high centers. So our expectation is that a differentiated REMS, the differentiated label, and an overall profile are going to drive differentiated use once physicians clearly grasp that. So that's how we've been approaching it.

Caroline Poacher

analyst
#24

Caroline Poacher here, filling in for Tess Romero from JPMorgan. We've just got one question about aficamten and oHCM. Recognizing that the late cycle meeting happened on September 15, could you say whether the REMS has been finalized at this stage of the review? If it hasn't, which items of the REMS still need to be finalized? And when do you think that would be done?

Robert Blum

executive
#25

So our interactions with FDA are ongoing, and those matters have not been finalized. We do expect that we're moving toward enabling their finalization so that the PDUFA date can be met. That said, we've had exchanges and interactions — and as I've said before, our belief is that what we're engaging on isn't the framework, but rather certain operational details, items that relate more to things such as web pages and administrative matters. Those are the things we think should come together to enable FDA to review this and hopefully approve it in time for the PDUFA date.

Maxwell Skor

analyst
#26

Just one more thing about ACACIA. Can you verify if ODYSSEY and ACACIA have any trial sites in common, and roughly what number — what percentage overlap? If they do, what effect could that have on something like a placebo response or other things that matter when reading the ACACIA data?

Fady Malik

executive
#27

Max, the precise overlap I can't provide, though it isn't particularly big. Clearly, if sites were running 2 studies at the same time in the same patients, that would be somewhat problematic. Certain trials had already completed their commitment and then obviously turned into a case of sites afterward and such. But I don't believe the overlap is particularly big. We generally ended up going to sites where we already had experience or had visited ourselves, whether through our HCM team or the clinical operations group. So we chose a cadre of sites across South America, Europe, North America, Australia, China, Israel that reflected either our own prior experience or clearly had experience in other HCM trials.

Yasmeen Rahimi

analyst
#28

This one might be for Andrew. Your presentation of the commercial plan was really well done. What's your thinking on price? From what you said, it sounds as though you're considering a price at parity with mavacamten. Given the profile of the product, you clearly could have room to price it higher. Any details on that would be welcome.

Andrew Callos

executive
#29

Sure; once our price is set, we'll share it. But consider this: when a second product enters a category that already has a price, it usually lands close to the first product's price; so my expectation is that we'll be in roughly that same vicinity, plus or minus perhaps a modest percentage, but we will definitely be within that range.

Roanna Ruiz

analyst
#30

As a quick follow-up about aficamten possibly launching in the U.S., can you share more detail on how long you expect the switch to commercial drug to take, and how well patients stick with it over time? Also, have you picked up anything about how often early adopters are likely to prescribe aficamten?

Andrew Callos

executive
#31

Certainly, and thanks for the question. When it comes to conversion, payers will initially have blocks in place while they conduct reviews, and the medical exception route is definitely the one that will be used. That process might move quickly — around 2 to 3 weeks — or it might stretch to 90 days. It really comes down to the specific plan, the individual physician's practice, how the paperwork is handled, and whether everything meets the requirements that plan has set. Within that window, though, my expectation is that we'll have patient support programs in place, and for those on commercial insurance we can carry them through the process. With Medicare, obviously that isn't an option, so for people who qualify we'll supply the medication at no cost through patient assistance. That's the way I'd frame the timeline for conversion while access is still limited. On the adherence side, what we're observing, at least within this particular class, is that both compliance and persistency come in above what you'd typically find with other cardiovascular medications. My guess is that, given how long it takes for patients to receive our drug and the dedication required to undergo echos and similar procedures, compliance after two years will probably remain somewhere above 50%. And then, what was your third question again — could you remind me?

Roanna Ruiz

analyst
#32

Yeah. That final section dealt with physicians who adopt early and write scripts for aficamten right from the start.

Andrew Callos

executive
#33

Right. It's an extremely concentrated market — roughly 650 prescribers, which represents around 80% of it. Those people are ones we know quite well. In fact, we've already engaged with a large number of them. During the opening weeks following launch, we'll reach out to nearly all of them, if not every single one. Consider those heavy prescribers, so to speak — even from the market research we conducted as recently as the past month or so, MAPLE combined with SEQUOIA heightens how urgently they feel about treating patients. As a result, we anticipate seeing elevated usage, so to speak, compared with other doctors among those who were early adopters for CMIs, and we ought to witness the same pattern with aficamten should it secure approval. That's what we're looking for.

Mayank Mamtani

analyst
#34

Strong third quarter. I'd really like to hear what you think — maybe this is for Andrew — regarding your most current view on peak penetration for CMI drugs. Perhaps you could also speak to where that penetration sits today and what you'd expect across scenarios for where it might go in the near term, 1 to 2 years; and as you mentioned regarding the effect of the MAPLE-HCM data, plus plenty of real-world data arriving from your peers, including at AHA. If you might speak to that, it would be useful. And a related subpart question concerned certain patient navigator training efforts that occur around the time you have a label in hand. I was just wondering whether any main FAQs or pushbacks you're getting ready for would also be useful to hear about.

Andrew Callos

executive
#35

That's quite a few questions, so I'll do my best to cover them. CMI penetration, I believe, was your first one. At present, penetration likely falls within 15% to 20% among oHCM, and by that I mean the count of eligible patients — those who are Class II, Class III, those receiving treatment with the CMI. So, as we've consistently stated, we anticipate roughly 80% or so of the market being available, which means patients who qualify, yet aren't on a CMI right now. Our expectation is that penetration likely rises by approximately 5 percentage points annually. So whenever you consider real-world evidence, whenever you consider further trials, that will definitely push penetration higher. Should guidelines be affected, should MAPLE help sway guidelines in '26 or '27, that will definitely speed up penetration; so I believe there are factors that could alter the trajectory of penetration, but that's the current state. Regarding training, we did supply the label to the FDA. We've received a few rounds of feedback. I think we've hinted at that. I think we can definitely train on a draft label and afterward we'll train once more on the final. That's fairly standard for how you'd train in relation to a label and in relation to a REMS.

Joe Pantginis

analyst
#36

I'm curious — shifting topics completely now to omecamtiv mecarbil. As things stand, the guidance indicates that enrollment will keep going into 2026. At what point do you expect to give more visibility regarding sites and enrollment figures? And what degree of clarity do you think we can get, beginning in '26?

Robert Blum

executive
#37

Perhaps we'll have Stuart address that, please.

Stuart Kupfer

executive
#38

Like I said, our site activation efforts are moving along nicely. In North America and Europe, 75% of sites are now activated. Screening is increasing, and randomization is increasing too. I'd say we aren't yet at the stage where we can begin giving out those figures, since I believe we'll wait until every site is activated and we have a solid trajectory. Still, things look good up to now. The study is being conducted well, along with site interaction and screening.

Robert Blum

executive
#39

Alright Joe, so once we get into the new year and gain a clearer picture of how enrollment is going at those newly activated sites, we ought to be in a position to narrow that guidance down toward an expectation for when enrollment could wrap up. And after that, as you're aware, this trial is gathering events; it's driven by events, and perhaps we can speak in broader terms about when data might arrive.

Paul Choi

analyst
#40

regarding the CAMELLIA trial you're running with a partner, I'd like to know whether you can share any timing updates, and perhaps give us some help in thinking about when that partner could launch in Japan — what would be a sensible assumption there? Then, for the AMBER study in HFpEF, might you be able to present some initial data from it during 2026?

Robert Blum

executive
#41

Robert I. Blum, answer: I'll have Fady address those, please.

Fady Malik

executive
#42

Sure. So when it comes to how the oHCM trial is advancing in Japan, the approach there is going to depend a bit more on both ACACIA and CAMELLIA wrapping up. Our expectation is that they'll finish around the same point in time, and each of them will feed into regulatory conversations and eventually an approval in that country. So at this stage I'm not able to offer anything concrete about where things stand, though CAMELLIA is progressing in a way that matches what we anticipated. As for AMBER, I'd say it's still too soon for us to make any commitment about data arriving in 2026. We'll likely have more to share on that around the time of our next earnings call.

John Gionco

analyst
#43

John Gionco here, filling in for Serge. Now that everyone can see the MAPLE results, I'm wondering about your expected timing — how soon would you want to submit the sNDA so that this data gets added to the API label, and do you expect that including it would change how treating physicians prescribe?

Robert Blum

executive
#44

I'll handle the first half, and Andrew can take the second. Our aim, assuming aficamten wins approval on the strength of SEQUOIA by the close of this year, is to move quickly and file a supplemental NDA built on MAPLE data in early 2026, which would allow a possible label expansion, perhaps as soon as the end of 2026. Andrew can speak to how that might play into broader use.

Andrew Callos

executive
#45

We have run this test multiple times, with the latest one coming in the current quarter. Every single instance, the result is a higher top line from greater CMI use, meaning CMI penetration rises, along with a bigger brand share for aficamten — or preferential share, to put it another way. So you end up with a bigger market and a bigger piece of it. If you break it down by segment, the core users essentially tell us this confirms safety and efficacy, which strengthens their conviction even further. As for the heavy beta blocker group, it genuinely calls into question their confidence in how well beta blockers work. Their urgency to treat, or urgency to refer, goes up. That second group, I think, will take somewhat more time — for some of them, guidelines plus ongoing education and promotion will definitely keep moving them along. So at a high level, what we anticipate is a bigger market, a bigger share, and we definitely view this as one of the expansion strategies we've discussed when it comes to a bigger market.

Kripa Devarakonda

analyst
#46

Alex filling in for Kripa here. Given what you've told us about the recent late-cycle meeting with the FDA and what the day 120 List of Questions from the CHMP looks like, is there any signal we ought to be watching for that would suggest the REMS condition might end up being substantially different between the U.S. and the EU?

Robert Blum

executive
#47

So, in the EU there's no REMS condition at all. As you're aware, that's entirely managed via labeling; however, regarding what you asked, our expectation is that aficamten, should it gain approval in the U.S; and in the EU will be handled in a comparable way when it comes to mitigating risk.

Jason Zemansky

analyst
#48

Nice work on the momentum. Perhaps to shift topics, though, with your latest balance sheet changes, how well positioned are you to back both the U.S. and EU launches? In other words, do you expect you'll need to raise more money, particularly considering what you're projecting for the launch?

Sung Lee

executive
#49

Jason, it's Sung. I appreciate the question. We can't say future financing won't happen. That said, we anticipate closing out the year with $2.2 billion in cash and investments — sorry. $1.2 billion. Thank you. I got a bit carried away there. So that leaves us quite strongly positioned, not just to launch aficamten in the U.S., but also to keep expanding in the EU and, crucially, to keep moving our pipeline forward. Remember that we can potentially tap additional capital of as much as $175 million; that comes from the Tranche 7 loan provided by Royalty Pharma. So we'll keep evaluating our choices regarding capital needs and capital structure.

Analyst

analyst
#50

Natalie here, filling in for Ash Verma from UBS, and we had one quick item regarding nHCM. I realize there's been considerable conversation around how heterogeneous this patient group is. Have you been able to determine whether a particular subset of patients gains the greatest benefit from CMI?

Fady Malik

executive
#51

So, my response would be that this remains an open question — perhaps we'll need to look at both the ODYSSEY data and the ACACIA data once those become available. Our thinking is that we should enroll patients who are symptomatic, who show the classic HCM phenotype — the classic HCM phenotype visible through echocardiography — and who have particular biomarker elevations. All of that, I believe, points to a population that is symptomatic, highly symptomatic, and functionally limited. Drawing on what we learned previously in REDWOOD, we believe such a population ought to respond to aficamten. So I suspect we'll be able to say more once we have the ACACIA data next year.

Robert Blum

executive
#52

One more point I'd make is that for more than 2 years, we've been tracking a group of patients with Nonobstructive disease, and most of them are showing good symptomatic responses as well as gains in cardiac biomarkers. So what we've seen up to now, at least among this FOREST cohort, looks like a fairly broad treatment response improvement.

Robert Blum

executive
#53

Appreciate it. My gratitude goes out to everyone who joined us on this call. Thanks as well for sticking with us and for the attention you've shown toward Cytokinetics. That brings our Q3 earnings call to a close, and my hope is that when we gather again for one of these calls, we'll be discussing what may be the first possible approval for aficamten and a product stemming from the research and development work we've done over many years — a truly significant milestone for this company and for everyone with a stake in it, our shareholders included. So with that, operator, let's wrap up the call now.

Operator

operator
#54

Thank you. And everyone, we appreciate your presence on this Cytokinetics Q3 2025 earnings call. At this point, you're welcome to hang up your phones.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Cytokinetics, Incorporated transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Cytokinetics, Incorporated earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Cytokinetics, Incorporated or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.